[1] HOUSE A A,ANAND I,BELLOMO R,et al.Definition and classification of Cardio-renal syndromes:workgroup statements from the 7th ADQI Consensus Conference[J].Nephrol Dial Transplant,2010,25(5):1416-1420.
[2] FU K,HU Y,ZHANG H,et al.Insights of worsening renal function in type 1 cardiorenal syndrome:from the pathogenesis,biomarkers to treatment[J].Front Cardiovasc Med,2021,8:760152.
[3] KHWAJA A.KDIGO clinical practice guidelines for acute kidney injury[J].Nephron Clin Pract,2012,120(4):c179-184.
[4] VANDENBERGHE W,GEVAERT S,KELLUM J A,et al.Acutekidney injury in cardiorenal syndrome type 1 patients:a systematic review and Meta-analysis[J].Cardiorenal Med,2016,6(2):116-128.
[5] GHIONZOLI N,SCIACCALUGA C,MANDOLI G,et al.Cardiogenic shock and acute kidney injury:the rule rather than the exception[J].Heart Fail Rev,2021,26(3):487-496.
[6] CARANDE E J,BROWN K,JACKSON D,et al.Acutekidney injury following percutaneous coronary intervention for acute coronary syndrome:incidence,aetiology,risk factors and outcomes[J].Angiology,2022,73(2):139-145.
[7] FAN Z,LI Y,JI H,et al.Nomogram model to predict cardiorenal syndrome type 1 in patients with acute heart failure[J].Kidney Blood Press Res,2018,43(6):1832-1841.
[8] CHEN J J,LEE T H,KUO G,et al.Acutekidney disease after acute decompensated heart failure[J].Kidney Int Rep,2022,7(3):526-536.
[9] SCHMUCKER J,FACH A,BECKER M,et al.Predictors of acute kidney injury in patients admitted with ST-elevation myocardial infarction—results from the Bremen STEMI-Registry[J].Eur Heart J Acute Cardiovasc Care,2018,7(8):710-722.
[10] HU W,HE W,LIU W,et al.Risk factors and prognosis of cardiorenal syndrome type 1 in elderly Chinese patients:a retrospective observational cohort study[J].Kidney Blood Press Res,2016,41(5):672-679.
[11] HORTON W B,BARRETT E J.Microvascular dysfunction in diabetes mellitus and cardiometabolic disease[J].Endocr Rev,2021,42(1):29-55.
[12] 秦雨晗,汤成春.造影剂肾病的研究进展[J].东南大学学报(医学版),2019,38(4):722-727.
[13] SOKOLSKI M,ZYMLISKI R,SOKOLSKA J M,et al.True worsening renal function identifies patients with acute heart failure with an ominous outcome[J].Pol Arch Intern Med,2019,129(5):357-360.
[14] AHMAD T,JACKSON K,RAO V S,et al.Worseningrenal function in patients with acute heart failure undergoing aggressive diuresis is not associated with tubular injury[J].Circulation,2018,137(19):2016-2028.
[15] FORMAN D E,BUTLER J,WANG Y,et al.Incidence,predictors at admission,and impact of worsening renal function among patients hospitalized with heart failure[J].J Am Coll Cardiol,2004,43(1):61-67.
[16] CAI D,XIAO T,ZOU A,et al.Predicting acute kidney injury risk in acute myocardial infarction patients:An artificial intelligence model using medical information mart for intensive care databases[J].Front Cardiovasc Med,2022,9:964894.
[17] THIND G S,LOEHRKE M,WILT J L.Acute cardiorenal syndrome:Mechanisms and clinical implications[J].Cleve Clin J Med,2018,85(3):231-239.
[18] NOHRIA A,HASSELBLAD V,STEBBINS A,et al.Cardiorenal interactions:insights from the ESCAPE trial[J].J Am Coll Cardiol,2008,51(13):1268-1274.
[19] SCAGLIOLA R,BRUNELLI C.Venous congestion and systemic hypoperfusion in cardiorenal syndrome:two sides of the same coin[J].Rev Cardiovasc Med,2022,23(3):111.
[20] RUOCCO G,PALAZZUOLI A,TER MAATEN J M.The role of the kidney in acute and chronic heart failure[J].Heart Fail Rev,2020,25(1):107-118.
[21] GEMBILLO G,VISCONTI L,GIUSTI M A,et al.Cardiorenalsyndrome:new pathways and novel biomarkers[J].Biomolecules,2021,11(11):1581.
[22] LUO X,JIN Q,WU Y.Tolvaptan add-on therapy in patients with acute heart failure:a systematic review and meta-analysis[J].Pharmacol Res Perspect,2020,8(3):e00614.
[23] CLEMENTI A,VIRZÌ G M,BATTAGLIA G G,et al.Neurohormonal,endocrine,and immune dysregulation and inflammation in cardiorenal syndrome[J].Cardiorenal Med,2019,9(5):265-273.
[24] VIRZÌ G M,BREGLIA A,BROCCA A,et al.Levels of proinflammatory cytokines,oxidative stress,and tissue damage markers in patients with acute heart failure with and without cardiorenal syndrome type 1[J].Cardiorenal Med,2018,8(4):321-331.
[25] LINHART C,ULRICH C,GREINERT D,et al.Systemic inflammation in acute cardiorenal syndrome:an observational pilot study[J].ESC Heart Fail,2018,5(5):920-930.
[26] RANGASWAMI J,BHALLA V,BLAIR J E A,et al.Cardiorenalsyndrome:classification,pathophysiology,diagnosis,and treatment strategies:a scientific statement from the american heart association[J].Circulation,2019,139(16):e840-e878.
[27] TAKAHAMA H,NISHIKIMI T,TAKASHIO S,et al.Change in the NT-proBNP/mature BNP molar ratio precedes worsening renal function in patients with acute heart failure:a novel predictor candidate for cardiorenal syndrome[J].J Am Heart Assoc,2019,8(17):e011468.
[28] ZHAO H L,HU H J,ZHAO X J,et al.Urine N-terminal pro-B-type natriuretic peptide and plasma proenkephalin are promising biomarkers for early diagnosis of cardiorenal syndrome type 1 in acute decompensated heart failure:a prospective,double-center,observational study in real-world[J].Ren Fail,2022,44(1):1486-1497.
[29] GEBERT L F R,MACRAE I J.Regulation of microRNA function in animals[J].Nat Rev Mol Cell Biol,2019,20(1):21-37.
[30] LIU J,ZHANG H,LI X,et al.Diagnostic and prognostic significance of aberrant miR-652-3p levels in patients with acute decompensated heart failure and acute kidney injury[J].J Int Med Res,2020,48(11):300060520967829.
[31] TEMPLETON E M,CAMERON V A,PICKERING J W,et al.Emerging microRNA biomarkers for acute kidney injury in acute decompensated heart failure[J].Heart Fail Rev,2021,26(5):1203-1217.
[32] ZHANG H,LIU J,LI X,et al.MicroRNA-423-5p as a biomarker for early diagnosis and outcome prediction of acute kidney injury in patients with acute decompensated heart failure[J].Int J Urol,2021,28(1):25-32.
[33] FELKER G M,LEE K L,BULL D A,et al.Diuretic strategies in patients with acute decompensated heart failure[J].N Engl J Med,2011,364(9):797-805.
[34] THOLÉN M,RICKSTEN S-E,LANNEMYR L.Effects of levosimendan on renal blood flow and glomerular filtration in patients with acute kidney injury after cardiac surgery:a double blind,randomized placebo-controlled study[J].Crit Care,2021,25(1):207.
[35] TEERLINK J R,COTTER G,DAVISON B A,et al.Serelaxin,recombinant human relaxin-2,for treatment of acute heart failure(RELAX-AHF):a randomised,placebo-controlled trial[J].Lancet,2013,381(9860):29-39.
[36] KIN H,MATSUMURA K,YAMAMOTO Y,et al.Renoprotective effect of tolvaptan in patients with new-onset acute heart failure[J].ESC Heart Fail,2020,7(4):1764-1770.
[37] SCHAUBROECK H A,GEVAERT S,BAGSHAW S M,et al.Acutecardiorenal syndrome in acute heart failure:focus on renal replacement therapy[J].Eur Heart J Acute Cardiovasc Care,2020,9(7):802-811.
[38] BART B A,GOLDSMITH S R,LEE K L,et al.Ultrafiltration in decompensated heart failure with cardiorenal syndrome[J].N Engl J Med,2012,367(24):2296-2304. |
